Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAM2000 Dose Finding in Previously Vaccinated Adults
NCT00053482Phase 2Completed
- Sponsor
- Emergent BioSolutions
- Start
- Jan 2003
- Primary completion
- Apr 2003
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of smallpox (vaccinia) vaccine, live in smallpox (5 arms), sponsored by Emergent BioSolutions. Primary endpoints: Neutralizing Antibody Response Titers at Day 30, Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers at Day 30 and 1 more. Started Jan 2003; status: completed.
02
Drugs
smallpox (vaccinia) vaccine, live
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00053482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053482.